Jane Street Group LLC Lowers Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Jane Street Group LLC trimmed its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 96.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,977 shares of the company's stock after selling 318,465 shares during the quarter. Jane Street Group LLC's holdings in Stoke Therapeutics were worth $132,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in STOK. KLP Kapitalforvaltning AS bought a new stake in Stoke Therapeutics during the fourth quarter worth about $63,000. Teacher Retirement System of Texas bought a new stake in Stoke Therapeutics during the fourth quarter worth about $113,000. Tower Research Capital LLC TRC lifted its stake in shares of Stoke Therapeutics by 70.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock valued at $132,000 after acquiring an additional 4,918 shares during the last quarter. Invesco Ltd. bought a new stake in shares of Stoke Therapeutics in the 4th quarter valued at about $133,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Stoke Therapeutics by 51.2% in the 4th quarter. Wells Fargo & Company MN now owns 16,786 shares of the company's stock valued at $185,000 after acquiring an additional 5,682 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on STOK shares. HC Wainwright lowered their target price on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Chardan Capital reaffirmed a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Cantor Fitzgerald raised Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Stoke Therapeutics has an average rating of "Buy" and a consensus price target of $23.20.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the sale, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. This trade represents a 6.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the sale, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. This represents a 5.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,748 shares of company stock worth $225,687. Insiders own 11.30% of the company's stock.

Stoke Therapeutics Trading Up 1.2%

Shares of STOK stock traded up $0.14 during midday trading on Wednesday, reaching $11.50. 401,125 shares of the stock were exchanged, compared to its average volume of 700,919. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $17.58. The company's 50 day moving average is $9.07 and its two-hundred day moving average is $9.66. The firm has a market cap of $627.87 million, a PE ratio of -5.48 and a beta of 1.09.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, equities analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.